|
1
|
Mylonas CC and Lazaris AC: Colorectal
cancer and basement membranes: Clinicopathological correlations.
Gastroenterol Res Pract. 2014:5801592014. View Article : Google Scholar
|
|
2
|
Abdalla EK, Adam R, Bilchik AJ, Jaeck D,
Vauthey JN and Mahvi D: Improving resectability of hepatic
colorectal metastases: Expert consensus statement. Ann Surg Oncol.
13:1271–1280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ameri K, Luong R, Zhang H, Powell AA,
Montgomery KD, Espinosa I, Bouley DM, Harris AL and Jeffrey SS:
Circulating tumour cells demonstrate an altered response to hypoxia
and an aggressive phenotype. Br J Cancer. 102:561–569. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hockel M, Schlenger K, Aral B, Mitze M,
Schaffer U and Vaupel P: Association between tumor hypoxia and
malignant progression in advanced cancer of the uterine cervix.
Cancer Res. 56:4509–4515. 1996.PubMed/NCBI
|
|
5
|
Chu CY, Jin YT, Zhang W, Yu J, Yang HP,
Wang HY, Zhang ZJ, Liu XP and Zou Q: CA IX is upregulated in
CoCl2-induced hypoxia and associated with cell invasive
potential and a poor prognosis of breast cancer. Int J Oncol.
48:271–280. 2016.
|
|
6
|
Dai ZJ, Gao J, Ma XB, Yan K, Liu XX, Kang
HF, Ji ZZ, Guan HT and Wang XJ: Up-regulation of hypoxia inducible
factor-1α by cobalt chloride correlates with proliferation and
apoptosis in PC-2 cells. J Exp Clin Cancer Res. 31:282012.
View Article : Google Scholar
|
|
7
|
Semenza GL: Hypoxia-inducible factor 1
(HIF-1) pathway. Sci STKE. 2007:cm82007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan Y, Hilliard G, Ferguson T and
Millhorn DE: Cobalt inhibits the interaction between
hypoxia-inducible factor alpha and von Hippel-Lindau protein by
direct binding to hypoxia-inducible factor-alpha. J Biol Chem.
278:15911–15916. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goldberg MA, Gaut CC and Bunn HF:
Erythropoietin mRNA levels are governed by both the rate of gene
transcription and posttranscriptional events. Blood. 77:271–277.
1991.PubMed/NCBI
|
|
10
|
Vengellur A and LaPres JJ: The role of
hypoxia inducible factor 1alpha in cobalt chloride induced cell
death in mouse embryonic fibroblasts. Toxicol Sci. 82:638–646.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang GL and Semenza GL: Desferrioxamine
induces erythropoietin gene expression and hypoxia-inducible factor
1 DNA-binding activity: Implications for models of hypoxia signal
transduction. Blood. 82:3610–3615. 1993.PubMed/NCBI
|
|
12
|
Ramaekers CH, van den Beucken T, Meng A,
Kassam S, Thoms J, Bristow RG and Wouters BG: Hypoxia disrupts the
Fanconi anemia pathway and sensitizes cells to chemotherapy through
regulation of UBE2T. Radiother Oncol. 101:190–197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pouysségur J, Dayan F and Mazure NM:
Hypoxia signalling in cancer and approaches to enforce tumour
regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Juliano RL and Ling V: A surface
glycoprotein modulating drug permeability in Chinese hamster ovary
cell mutants. Biochim Biophys Acta. 455:152–162. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cole SP, Bhardwaj G, Gerlach JH, Mackie
JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and
Deeley RG: Overexpression of a transporter gene in a
multidrug-resistant human lung cancer cell line. Science.
258:1650–1654. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sasi N, Hwang M, Jaboin J, Csiki I and Lu
B: Regulated cell death pathways: New twists in modulation of BCL2
family function. Mol Cancer Ther. 8:1421–1429. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhutia SK, Mallick SK, Maiti S and Maiti
TK: Antitumor and proapoptotic effect of Abrus agglutinin derived
peptide in Dalton's lymphoma tumor model. Chem Biol Interact.
174:11–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toffoli S and Michiels C: Intermittent
hypoxia is a key regulator of cancer cell and endothelial cell
interplay in tumours. FEBS J. 275:2991–3002. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goldberg MA and Schneider TJ: Similarities
between the oxygen-sensing mechanisms regulating the expression of
vascular endothelial growth factor and erythropoietin. J Biol Chem.
269:4355–4359. 1994.PubMed/NCBI
|
|
23
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gleadle JM and Ratcliffe PJ: Induction of
hypoxia-inducible factor-1, erythropoietin, vascular endothelial
growth factor, and glucose transporter-1 by hypoxia: Evidence
against a regulatory role for Src kinase. Blood. 89:503–509.
1997.PubMed/NCBI
|
|
25
|
Mabjeesh NJ and Amir S: Hypoxia-inducible
factor (HIF) in human tumorigenesis. Histol Histopathol.
22:559–572. 2007.PubMed/NCBI
|
|
26
|
Wu XY, Fu ZX and Wang XH: Effect of
hypoxia-inducible factor 1-α on Survivin in colorectal cancer. Mol
Med Rep. 3:409–415. 2010.
|
|
27
|
Piret JP, Lecocq C, Toffoli S, Ninane N,
Raes M and Michiels C: Hypoxia and CoCl2 protect HepG2
cells against serum deprivation- and t-BHP-induced apoptosis: A
possible anti-apoptotic role for HIF-1. Exp Cell Res. 295:340–349.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Greijer AE and van der Wall E: The role of
hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J
Clin Pathol. 57:1009–1014. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar
KR and Li WD: Lung resistance protein and multidrug resistance
protein in non-small cell lung cancer and their clinical
significance. J Int Med Res. 39:1693–1700. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Linn SC, Pinedo HM, van Ark-Otte J, van
der Valk P, Hoekman K, Honkoop AH, Vermorken JB and Giaccone G:
Expression of drug resistance proteins in breast cancer, in
relation to chemotherapy. Int J Cancer. 71:787–795. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
O'Driscoll L, Walsh N, Larkin A, Ballot J,
Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J and Kennedy S:
MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic
carcinoma. Anticancer Res. 27:2115–2120. 2007.PubMed/NCBI
|
|
32
|
Erler JT, Cawthorne CJ, Williams KJ,
Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C,
Stratford IJ and Dive C: Hypoxia-mediated down regulation of Bid
and Bax in tumors occurs via hypoxia-inducible factor 1-dependent
and -independent mechanisms and contributes to drug resistance. Mol
Cell Biol. 24:2875–2889. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
An WG, Kanekal M, Simon MC, Maltepe E,
Blagosklonny MV and Neckers LM: Stabilization of wild-type p53 by
hypoxia-inducible factor 1alpha. Nature. 392:405–408. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bruick RK: Expression of the gene encoding
the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad
Sci USA. 97:9082–9087. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin CP, Guan SH, Zhang B, Wang XX and Yue
SW: Upregulation of HIF-1α protects neuroblastoma cells from
hypoxia-induced apoptosis in a RhoA-dependent manner. Mol Med Rep.
12:7123–7131. 2015.PubMed/NCBI
|
|
36
|
Wang X, Li J, Wu D, Bu X and Qiao Y:
Hypoxia promotes apoptosis of neuronal cells through
hypoxia-inducible factor-1α-microRNA-204-B-cell lymphoma-2 pathway.
Exp Biol Med (Maywood). 241:177–183. 2016. View Article : Google Scholar
|
|
37
|
Pettersson F, Dalgleish AG, Bissonnette RP
and Colston KW: Retinoids cause apoptosis in pancreatic cancer
cells via activation of RAR-gamma and altered expression of
Bcl-2/Bax. Br J Cancer. 87:555–561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Letai A, Bassik MC, Walensky LD,
Sorcinelli MD, Weiler S and Korsmeyer SJ: Distinct BH3 domains
either sensitize or activate mitochondrial apoptosis, serving as
prototype cancer therapeutics. Cancer Cell. 2:183–192. 2002.
View Article : Google Scholar : PubMed/NCBI
|
